I also reckon the lack of discussion on FTO after the introduction was a little weird.
My take on it, as much as RAC investors would love "FTO saves the day" highlighted for the world to see, there is only so much space on a conference presentation poster.
I take solace in the fact the intro connects the dots between bisantrene being an effective FTO inhibitor and FTO inhibition sensitizes AML cells to HMA's (decitabine). The results listed afterwards are positive and seem to support the hypothesis so I'm not worrying too much. I only hope the publication discusses FTO and the MOA in further detail.
I also reckon the lack of discussion on FTO after the...
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.89 |
Change
0.120(6.80%) |
Mkt cap ! $321.0M | |||
| Open | High | Low | Value | Volume |
| $1.78 | $1.93 | $1.78 | $563.4K | 302.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 108 | $1.88 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.90 | 4926 | 1 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |